医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Manhattan Scientifics Seed Funded Imagion Bioscience & Owns 64 Million Shares IBX

2019年07月26日 AM02:55
このエントリーをはてなブックマークに追加


 

NEW YORK

Manhattan Scientifics (OTC; QB MHTX) announces its former wholly owned sub Imagion Bioscience (ASX:IBX) Receives A$2 million in R&D Tax Incentives from the Australian Government (ATO)

Bob Proulx, Executive Chairman of Imagion Biosystems, said: “We are very pleased to report to our shareholders that the tax incentive funds have been received and that the rebate came in higher than the A$1.7 million we originally expected. This cash infusion will significantly enhance our ability to advance the development of our ground-breaking diagnostic imaging technology which was recently designated by the U.S. Food and Drug Administration as a ‘Breakthrough Device’”.

About Manhattan Scientifics Inc.

Manhattan Scientifics is focused on the commercialization of disruptive technologies

Forward-looking statement:

This press release contains forward looking statements which are subject 5to a number of risks, assumptions and uncertainties. Mgt believes that purchase of our shares should be considered to be at the high end of the risk spectrum.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190725005680/en/

CONTACT

Marvin Maslow, Chairman: 917.923.3300

Manny Tsoupanarias, CEO : 917.688.4158

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • LetsGetChecked首发经FDA EUA核准的居家冠状病毒(COVID-19) Sure-track检测
  • FDA Accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA® (cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
  • LetsGetChecked、FDAのEUA承認を受けた在宅型コロナウイルス(COVID-19)検査用シュア・トラック・テストを発表
  • 欧盟委员会同意武田无需履行剥离夏尔后续化合物SHP647的承诺
  • Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time